Town & Country Bank & Trust CO dba First Bankers Trust CO cut its position in shares of Abbott Laboratories (NYSE:ABT) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,029 shares of the healthcare product maker’s stock after selling 289 shares during the quarter. Abbott Laboratories accounts for 1.3% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s portfolio, making the stock its 28th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Abbott Laboratories were worth $2,432,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Waldron LP raised its stake in shares of Abbott Laboratories by 41.0% in the first quarter. Waldron LP now owns 10,042 shares of the healthcare product maker’s stock valued at $442,000 after acquiring an additional 2,922 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Abbott Laboratories by 12.6% in the first quarter. Fisher Asset Management LLC now owns 16,656 shares of the healthcare product maker’s stock valued at $740,000 after acquiring an additional 1,862 shares during the last quarter. BTR Capital Management Inc. raised its stake in shares of Abbott Laboratories by 8.9% in the first quarter. BTR Capital Management Inc. now owns 137,418 shares of the healthcare product maker’s stock valued at $6,103,000 after acquiring an additional 11,268 shares during the last quarter. Profund Advisors LLC raised its stake in shares of Abbott Laboratories by 25.0% in the first quarter. Profund Advisors LLC now owns 69,149 shares of the healthcare product maker’s stock valued at $3,071,000 after acquiring an additional 13,808 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Abbott Laboratories by 8.7% in the first quarter. ProShare Advisors LLC now owns 1,538,527 shares of the healthcare product maker’s stock valued at $68,326,000 after acquiring an additional 123,779 shares during the last quarter. 71.50% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the transaction, the insider now directly owns 221,488 shares in the company, valued at $10,963,656. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $750,000.00. Following the transaction, the insider now owns 143,154 shares of the company’s stock, valued at $7,157,700. The disclosure for this sale can be found here. Insiders have sold 333,310 shares of company stock valued at $16,857,255 over the last quarter. Corporate insiders own 0.76% of the company’s stock.

Shares of Abbott Laboratories (NYSE ABT) traded up 1.169% during trading on Thursday, reaching $54.975. 2,511,788 shares of the company were exchanged. The stock’s 50-day moving average is $51.40 and its 200-day moving average is $47.64. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $54.98. The firm has a market cap of $95.52 billion, a price-to-earnings ratio of 76.996 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The business’s quarterly revenue was up 24.5% on a year-over-year basis. During the same period last year, the company posted $0.55 earnings per share. Equities research analysts predict that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.95%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 149.30%.

A number of research firms have recently issued reports on ABT. Bank of America Corporation reiterated a “buy” rating and issued a $60.00 target price (up previously from $56.00) on shares of Abbott Laboratories in a research note on Wednesday. BidaskClub cut shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research report on Thursday, June 29th. Morgan Stanley restated an “equal weight” rating on shares of Abbott Laboratories in a research report on Monday, July 10th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 21st. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and a consensus target price of $54.40.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/town-country-bank-trust-co-dba-first-bankers-trust-co-sells-289-shares-of-abbott-laboratories-abt/1610897.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.